The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review

Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial

Characterizing Improvements in Physical Functioning with PROMIS-PF and In-trial Exit Interviews: A Mixed-methods Analysis to Understand the Meaningful Changes Experienced by Patients on Vimseltinib in the MOTION Trial

The Burden of Surgery for Tenosynovial Giant Cell Tumor: A Targeted Review

A Mixed-Methods Analysis to Define Minimum Clinically Importance Differences (MCIDs) in Range of Motion, Physical Function, and Worst Stiffness in Patients with Tenosynovial Giant Cell Tumor (TGCT)

Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial

Safety, efficacy, and patient-reported outcomes with vimseltinib in patients with tenosynovial giant cell tumor who received prior anti–colony-stimulating factor 1 therapy: ongoing phase 2 study